B. Riley began coverage on shares of Catalyst Biosciences (NASDAQ:CBIO) in a research report sent to investors on Friday morning, MarketBeat.com reports. The firm issued a buy rating and a $19.00 price target on the biopharmaceutical company’s stock.

Separately, Zacks Investment Research upgraded Catalyst Biosciences from a hold rating to a buy rating and set a $5.25 price target on the stock in a research note on Wednesday, November 8th.

Catalyst Biosciences (NASDAQ:CBIO) opened at $8.31 on Friday. Catalyst Biosciences has a 12 month low of $3.11 and a 12 month high of $21.30.

Several institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its holdings in Catalyst Biosciences by 117.0% during the third quarter. Dimensional Fund Advisors LP now owns 173,555 shares of the biopharmaceutical company’s stock worth $873,000 after purchasing an additional 93,592 shares during the last quarter. Zacks Investment Management acquired a new position in Catalyst Biosciences during the second quarter worth $147,000. Virtu KCG Holdings LLC acquired a new position in Catalyst Biosciences during the second quarter worth $103,000. Vanguard Group Inc. raised its holdings in Catalyst Biosciences by 294.1% during the second quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 32,621 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Catalyst Biosciences during the second quarter worth $107,000. Hedge funds and other institutional investors own 31.47% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/catalyst-biosciences-cbio-now-covered-by-b-riley/1758513.html.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Receive News & Ratings for Catalyst Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.